statistiche ricercatore

Continente	#
NA - Nord America	631
AS - Asia	419
EU - Europa	369
SA - Sud America	87
Continente sconosciuto - Info sul continente non disponibili	87
AF - Africa	25
Totale	1.618

Nazione	#
US - Stati Uniti d'America	601
CN - Cina	177
IE - Irlanda	86
SG - Singapore	86
IT - Italia	82
BR - Brasile	68
DE - Germania	56
HK - Hong Kong	52
RU - Federazione Russa	42
VN - Vietnam	36
FI - Finlandia	32
IN - India	24
GB - Regno Unito	21
ZA - Sudafrica	21
CA - Canada	19
FR - Francia	15
CZ - Repubblica Ceca	8
ID - Indonesia	7
BD - Bangladesh	6
AR - Argentina	5
EC - Ecuador	5
SE - Svezia	5
CO - Colombia	4
ES - Italia	4
PK - Pakistan	4
PL - Polonia	4
TR - Turchia	4
VE - Venezuela	4
BE - Belgio	3
CH - Svizzera	3
IL - Israele	3
IQ - Iraq	3
JP - Giappone	3
GE - Georgia	2
GT - Guatemala	2
JM - Giamaica	2
MX - Messico	2
NL - Olanda	2
TW - Taiwan	2
UZ - Uzbekistan	2
AO - Angola	1
AT - Austria	1
AZ - Azerbaigian	1
BS - Bahamas	1
BY - Bielorussia	1
CR - Costa Rica	1
EG - Egitto	1
HN - Honduras	1
IM - Isola di Man	1
KE - Kenya	1
KZ - Kazakistan	1
LT - Lituania	1
MY - Malesia	1
NA - Namibia	1
NP - Nepal	1
OM - Oman	1
PA - Panama	1
PH - Filippine	1
PT - Portogallo	1
PY - Paraguay	1
SA - Arabia Saudita	1
SK - Slovacchia (Repubblica Slovacca)	1
SV - El Salvador	1
TH - Thailandia	1
Totale	1.531

Nome	#
Gut Microbiota Analysis in Postoperative Lynch Syndrome Patients	156
A phenotypic based target screening approach delivers new antitubercular CTP synthetase inhibitors	152
A multitarget approach to drug discovery inhibiting Mycobacterium tuberculosis PyrG and PanK	133
New antitubercular prodrugs with novel mechanisms of action	128
New and old hot drug targets in tuberculosis	125
Triazolophthalazines: Easily Accessible Compounds with Potent Antitubercular Activity.	123
New insights into the mechanism of action of the thienopyrimidine antitubercular prodrug TP053	119
Rv0579 Is Involved in the Resistance to the TP053 Antitubercular Prodrug	118
Identification of a New FtsZ Inhibitor by Virtual Screening, Mechanistic Insights, and Structure-Activity Relationship Analyses	118
The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase	116
Pyrazole and imidazo[1,2-b]pyrazole derivatives as new potential anti-tuberculosis agents.	114
Pyrrolidinone and pyrrolidine derivatives: Evaluation as inhibitors of InhA and Mycobacterium tuberculosis.	114
Mechanochemical Synthesis and Biological Evaluation of Novel Isoniazid Derivatives with Potent Antitubercular Activity.	102
Totale	1.618

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	57	0	0	0	0	2	0	0	2	2	3	10	38
2022/2023	183	20	20	3	4	12	19	0	4	96	0	5	0
2023/2024	128	17	18	0	4	6	21	4	20	1	4	25	8
2024/2025	272	9	21	6	4	9	28	16	18	60	10	35	56
2025/2026	583	56	35	84	90	66	24	85	37	46	29	19	12
2026/2027	135	15	26	34	50	10	0	0	0	0	0	0	0
Totale													1.618